Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice
Liver International · 2026
DOI: 10.1111/liv.70507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Xiaofei Yin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association, American Heart Association-American Stroke Association, Bayer AG.
Abstract (Originalsprache)
Background & Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) spans from simple steatosis to metabolic dysfunction‐associated steatohepatitis (MASH) and can progress to cirrhosis or hepatocellular carcinoma. Despite its prevalence, effective therapies are lacking. Recent genome‐wide association studies identified a common missense variant (rs2642438) in the Mitochondrial Amidoxime Reducing Component 1 ( MTARC1 ) gene that protects against liver cirrhosis without increasing cardiovascular disease risk. Biochemical and disease risk signatures associated with carriers of this missense variant also aligned with those of a known loss‐of‐function MTARC1 variant, suggesting mARC1 inhibition as a potential MASLD treatment.
Methods
To validate mARC1 loss‐of‐function as protective against MASLD, we generated Mtarc1 knockout (KO) mice and placed them on a choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD). Effects of Mtarc1 KO on obesity and type 2 diabetes were explored using a high‐fat diet. Hepatocytes from Mtarc1 KO mice were isolated to explore the molecular mechanisms by which Mtarc1 KO impacts lipid metabolism.
Results
Mtarc1 KO mice exhibited no vital growth or development defects. With a high‐fat diet‐induced obesity model, obese Mtarc1 KO mice exhibited reduced liver mass and lower cholesterol levels, with no effect on glucose homeostasis. In a CDAHFD‐induced MASLD model, mARC1 deficiency significantly reduced liver steatosis, profibrosis, and inflammation. Untargeted metabolomics profiling further showed hepatic enrichment of phospholipids in Mtarc1 KO mice. Primary hepatocytes isolated from Mtarc1 KO mice exhibited reduced lipid droplet accumulation, decreased fatty acid uptake, and increased lipid secretion.
Conclusions
These findings support mARC1 inhibition as a promising therapeutic strategy for MASLD/MASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Bayer U.S. LLC, Cambridge, Massachusetts, USA.
- Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Bayer AG, Pharmaceutical Division, Berlin, Germany.
- GI Division, Department of Medicine, Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Bryan MacDonald, Alison Leed
Förderung
- American Heart Association
- American Heart Association-American Stroke Association
- Bayer AG
- NHLBI NIH HHS
- European Union
- National Institutes of Health
- European Commission
- Bayer
Zitieren
APA
Yin, X., Bickerton, C., MacDonald, B., Arduini, A., Shi, Y., Haas, M., Deik, A., Chaffin, M., Kovacs-Bogdan, E., Pacheco, J. A., Amegadjie, M., Bhandary, B., Sadre, S., Rathjen, T., Papangeli, I., Chung, R. T., Goodman, R., Claussnitzer, M., Clish, C., …, & Ellinor, P. T. (2026). Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice. Liver International. https://doi.org/10.1111/liv.70507
Vancouver
Yin X, Bickerton C, MacDonald B, Arduini A, Shi Y, Haas M, et al. Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice. Liver International. 2026. doi:10.1111/liv.70507
BibTeX
@article{Yin2026,
author = {Yin, Xiaofei and Bickerton, Caroline and MacDonald, Bryan and Arduini, Alessandro and Shi, Yunlong and Haas, Mary and Deik, Amy and Chaffin, Mark and Kovacs-Bogdan, Erika and Pacheco, Julian Avila and Amegadjie, Maiwen and Bhandary, Bidur and Sadre, Shayan and Rathjen, Thomas and Papangeli, Irinna and Chung, Raymond T and Goodman, Russell and Claussnitzer, Melina and Clish, Clary and Ehrmann, Alexander and Leed, Alison and Ellinor, Patrick T},
title = {Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70507}
}
EUVIMED